Report cover image

Global Generic and Biosimilar Pharmaceuticals Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published May 17, 2025
Length 207 Pages
SKU # APRC20362000

Description

Summary

According to APO Research, The global Generic and Biosimilar Pharmaceuticals market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Generic and Biosimilar Pharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Generic and Biosimilar Pharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Generic and Biosimilar Pharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Generic and Biosimilar Pharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Generic and Biosimilar Pharmaceuticals include Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Amgen, AbbVie and Sanofi-Aventis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Generic and Biosimilar Pharmaceuticals, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Generic and Biosimilar Pharmaceuticals, also provides the revenue of main regions and countries. Of the upcoming market potential for Generic and Biosimilar Pharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Generic and Biosimilar Pharmaceuticals revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Generic and Biosimilar Pharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Generic and Biosimilar Pharmaceuticals revenue, projected growth trends, production technology, application and end-user industry.

Generic and Biosimilar Pharmaceuticals Segment by Company

Johnson & Johnson
Novartis
Merck
Roche
Eli Lilly
Pfizer
Amgen
AbbVie
Sanofi-Aventis
Novo Nordisk
Innovent
Gelgen
Ganlee
Dong Bao
CP Guojian
Changchun High Tech
Biotech
3sbio
Generic and Biosimilar Pharmaceuticals Segment by Type

Erythropoietin
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Other
Generic and Biosimilar Pharmaceuticals Segment by Application

Tumor
Hemophilia
Cardiovascular
Diabetes
Other
Generic and Biosimilar Pharmaceuticals Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic and Biosimilar Pharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic and Biosimilar Pharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic and Biosimilar Pharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Generic and Biosimilar Pharmaceuticals in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Generic and Biosimilar Pharmaceuticals company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic and Biosimilar Pharmaceuticals revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

207 Pages
1 Market Overview
1.1 Product Definition
1.2 Generic and Biosimilar Pharmaceuticals Market by Type
1.2.1 Global Generic and Biosimilar Pharmaceuticals Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Erythropoietin
1.2.3 Monoclonal Antibodies
1.2.4 Interferon
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Other
1.3 Generic and Biosimilar Pharmaceuticals Market by Application
1.3.1 Global Generic and Biosimilar Pharmaceuticals Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Tumor
1.3.3 Hemophilia
1.3.4 Cardiovascular
1.3.5 Diabetes
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Generic and Biosimilar Pharmaceuticals Market Dynamics
2.1 Generic and Biosimilar Pharmaceuticals Industry Trends
2.2 Generic and Biosimilar Pharmaceuticals Industry Drivers
2.3 Generic and Biosimilar Pharmaceuticals Industry Opportunities and Challenges
2.4 Generic and Biosimilar Pharmaceuticals Industry Restraints
3 Global Growth Perspective
3.1 Global Generic and Biosimilar Pharmaceuticals Market Perspective (2020-2031)
3.2 Global Generic and Biosimilar Pharmaceuticals Growth Trends by Region
3.2.1 Global Generic and Biosimilar Pharmaceuticals Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Generic and Biosimilar Pharmaceuticals Market Size by Region (2020-2025)
3.2.3 Global Generic and Biosimilar Pharmaceuticals Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Generic and Biosimilar Pharmaceuticals Revenue by Players
4.1.1 Global Generic and Biosimilar Pharmaceuticals Revenue by Players (2020-2025)
4.1.2 Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Players (2020-2025)
4.1.3 Global Generic and Biosimilar Pharmaceuticals Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Generic and Biosimilar Pharmaceuticals Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Generic and Biosimilar Pharmaceuticals Key Players Headquarters & Area Served
4.4 Global Generic and Biosimilar Pharmaceuticals Players, Product Type & Application
4.5 Global Generic and Biosimilar Pharmaceuticals Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Generic and Biosimilar Pharmaceuticals Market CR5 and HHI
4.6.3 2024 Generic and Biosimilar Pharmaceuticals Tier 1, Tier 2, and Tier 3
5 Generic and Biosimilar Pharmaceuticals Market Size by Type
5.1 Global Generic and Biosimilar Pharmaceuticals Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Generic and Biosimilar Pharmaceuticals Revenue by Type (2020-2031)
5.3 Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Type (2020-2031)
6 Generic and Biosimilar Pharmaceuticals Market Size by Application
6.1 Global Generic and Biosimilar Pharmaceuticals Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Generic and Biosimilar Pharmaceuticals Revenue by Application (2020-2031)
6.3 Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Comapny Information
7.1.2 Johnson & Johnson Business Overview
7.1.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.1.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product Portfolio
7.1.5 Johnson & Johnson Recent Developments
7.2 Novartis
7.2.1 Novartis Comapny Information
7.2.2 Novartis Business Overview
7.2.3 Novartis Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.2.4 Novartis Generic and Biosimilar Pharmaceuticals Product Portfolio
7.2.5 Novartis Recent Developments
7.3 Merck
7.3.1 Merck Comapny Information
7.3.2 Merck Business Overview
7.3.3 Merck Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.3.4 Merck Generic and Biosimilar Pharmaceuticals Product Portfolio
7.3.5 Merck Recent Developments
7.4 Roche
7.4.1 Roche Comapny Information
7.4.2 Roche Business Overview
7.4.3 Roche Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.4.4 Roche Generic and Biosimilar Pharmaceuticals Product Portfolio
7.4.5 Roche Recent Developments
7.5 Eli Lilly
7.5.1 Eli Lilly Comapny Information
7.5.2 Eli Lilly Business Overview
7.5.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.5.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Product Portfolio
7.5.5 Eli Lilly Recent Developments
7.6 Pfizer
7.6.1 Pfizer Comapny Information
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Product Portfolio
7.6.5 Pfizer Recent Developments
7.7 Amgen
7.7.1 Amgen Comapny Information
7.7.2 Amgen Business Overview
7.7.3 Amgen Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.7.4 Amgen Generic and Biosimilar Pharmaceuticals Product Portfolio
7.7.5 Amgen Recent Developments
7.8 AbbVie
7.8.1 AbbVie Comapny Information
7.8.2 AbbVie Business Overview
7.8.3 AbbVie Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.8.4 AbbVie Generic and Biosimilar Pharmaceuticals Product Portfolio
7.8.5 AbbVie Recent Developments
7.9 Sanofi-Aventis
7.9.1 Sanofi-Aventis Comapny Information
7.9.2 Sanofi-Aventis Business Overview
7.9.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.9.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product Portfolio
7.9.5 Sanofi-Aventis Recent Developments
7.10 Novo Nordisk
7.10.1 Novo Nordisk Comapny Information
7.10.2 Novo Nordisk Business Overview
7.10.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.10.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Product Portfolio
7.10.5 Novo Nordisk Recent Developments
7.11 Innovent
7.11.1 Innovent Comapny Information
7.11.2 Innovent Business Overview
7.11.3 Innovent Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.11.4 Innovent Generic and Biosimilar Pharmaceuticals Product Portfolio
7.11.5 Innovent Recent Developments
7.12 Gelgen
7.12.1 Gelgen Comapny Information
7.12.2 Gelgen Business Overview
7.12.3 Gelgen Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.12.4 Gelgen Generic and Biosimilar Pharmaceuticals Product Portfolio
7.12.5 Gelgen Recent Developments
7.13 Ganlee
7.13.1 Ganlee Comapny Information
7.13.2 Ganlee Business Overview
7.13.3 Ganlee Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.13.4 Ganlee Generic and Biosimilar Pharmaceuticals Product Portfolio
7.13.5 Ganlee Recent Developments
7.14 Dong Bao
7.14.1 Dong Bao Comapny Information
7.14.2 Dong Bao Business Overview
7.14.3 Dong Bao Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.14.4 Dong Bao Generic and Biosimilar Pharmaceuticals Product Portfolio
7.14.5 Dong Bao Recent Developments
7.15 CP Guojian
7.15.1 CP Guojian Comapny Information
7.15.2 CP Guojian Business Overview
7.15.3 CP Guojian Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.15.4 CP Guojian Generic and Biosimilar Pharmaceuticals Product Portfolio
7.15.5 CP Guojian Recent Developments
7.16 Changchun High Tech
7.16.1 Changchun High Tech Comapny Information
7.16.2 Changchun High Tech Business Overview
7.16.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.16.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Product Portfolio
7.16.5 Changchun High Tech Recent Developments
7.17 Biotech
7.17.1 Biotech Comapny Information
7.17.2 Biotech Business Overview
7.17.3 Biotech Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.17.4 Biotech Generic and Biosimilar Pharmaceuticals Product Portfolio
7.17.5 Biotech Recent Developments
7.18 3sbio
7.18.1 3sbio Comapny Information
7.18.2 3sbio Business Overview
7.18.3 3sbio Generic and Biosimilar Pharmaceuticals Revenue and Gross Margin (2020-2025)
7.18.4 3sbio Generic and Biosimilar Pharmaceuticals Product Portfolio
7.18.5 3sbio Recent Developments
8 North America
8.1 North America Generic and Biosimilar Pharmaceuticals Revenue (2020-2031)
8.2 North America Generic and Biosimilar Pharmaceuticals Revenue by Type (2020-2031)
8.2.1 North America Generic and Biosimilar Pharmaceuticals Revenue by Type (2020-2025)
8.2.2 North America Generic and Biosimilar Pharmaceuticals Revenue by Type (2026-2031)
8.3 North America Generic and Biosimilar Pharmaceuticals Revenue Share by Type (2020-2031)
8.4 North America Generic and Biosimilar Pharmaceuticals Revenue by Application (2020-2031)
8.4.1 North America Generic and Biosimilar Pharmaceuticals Revenue by Application (2020-2025)
8.4.2 North America Generic and Biosimilar Pharmaceuticals Revenue by Application (2026-2031)
8.5 North America Generic and Biosimilar Pharmaceuticals Revenue Share by Application (2020-2031)
8.6 North America Generic and Biosimilar Pharmaceuticals Revenue by Country
8.6.1 North America Generic and Biosimilar Pharmaceuticals Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Generic and Biosimilar Pharmaceuticals Revenue by Country (2020-2025)
8.6.3 North America Generic and Biosimilar Pharmaceuticals Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Generic and Biosimilar Pharmaceuticals Revenue (2020-2031)
9.2 Europe Generic and Biosimilar Pharmaceuticals Revenue by Type (2020-2031)
9.2.1 Europe Generic and Biosimilar Pharmaceuticals Revenue by Type (2020-2025)
9.2.2 Europe Generic and Biosimilar Pharmaceuticals Revenue by Type (2026-2031)
9.3 Europe Generic and Biosimilar Pharmaceuticals Revenue Share by Type (2020-2031)
9.4 Europe Generic and Biosimilar Pharmaceuticals Revenue by Application (2020-2031)
9.4.1 Europe Generic and Biosimilar Pharmaceuticals Revenue by Application (2020-2025)
9.4.2 Europe Generic and Biosimilar Pharmaceuticals Revenue by Application (2026-2031)
9.5 Europe Generic and Biosimilar Pharmaceuticals Revenue Share by Application (2020-2031)
9.6 Europe Generic and Biosimilar Pharmaceuticals Revenue by Country
9.6.1 Europe Generic and Biosimilar Pharmaceuticals Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Generic and Biosimilar Pharmaceuticals Revenue by Country (2020-2025)
9.6.3 Europe Generic and Biosimilar Pharmaceuticals Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China Generic and Biosimilar Pharmaceuticals Revenue (2020-2031)
10.2 China Generic and Biosimilar Pharmaceuticals Revenue by Type (2020-2031)
10.2.1 China Generic and Biosimilar Pharmaceuticals Revenue by Type (2020-2025)
10.2.2 China Generic and Biosimilar Pharmaceuticals Revenue by Type (2026-2031)
10.3 China Generic and Biosimilar Pharmaceuticals Revenue Share by Type (2020-2031)
10.4 China Generic and Biosimilar Pharmaceuticals Revenue by Application (2020-2031)
10.4.1 China Generic and Biosimilar Pharmaceuticals Revenue by Application (2020-2025)
10.4.2 China Generic and Biosimilar Pharmaceuticals Revenue by Application (2026-2031)
10.5 China Generic and Biosimilar Pharmaceuticals Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Generic and Biosimilar Pharmaceuticals Revenue (2020-2031)
11.2 Asia Generic and Biosimilar Pharmaceuticals Revenue by Type (2020-2031)
11.2.1 Asia Generic and Biosimilar Pharmaceuticals Revenue by Type (2020-2025)
11.2.2 Asia Generic and Biosimilar Pharmaceuticals Revenue by Type (2026-2031)
11.3 Asia Generic and Biosimilar Pharmaceuticals Revenue Share by Type (2020-2031)
11.4 Asia Generic and Biosimilar Pharmaceuticals Revenue by Application (2020-2031)
11.4.1 Asia Generic and Biosimilar Pharmaceuticals Revenue by Application (2020-2025)
11.4.2 Asia Generic and Biosimilar Pharmaceuticals Revenue by Application (2026-2031)
11.5 Asia Generic and Biosimilar Pharmaceuticals Revenue Share by Application (2020-2031)
11.6 Asia Generic and Biosimilar Pharmaceuticals Revenue by Country
11.6.1 Asia Generic and Biosimilar Pharmaceuticals Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Generic and Biosimilar Pharmaceuticals Revenue by Country (2020-2025)
11.6.3 Asia Generic and Biosimilar Pharmaceuticals Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Generic and Biosimilar Pharmaceuticals Revenue (2020-2031)
12.2 SAMEA Generic and Biosimilar Pharmaceuticals Revenue by Type (2020-2031)
12.2.1 SAMEA Generic and Biosimilar Pharmaceuticals Revenue by Type (2020-2025)
12.2.2 SAMEA Generic and Biosimilar Pharmaceuticals Revenue by Type (2026-2031)
12.3 SAMEA Generic and Biosimilar Pharmaceuticals Revenue Share by Type (2020-2031)
12.4 SAMEA Generic and Biosimilar Pharmaceuticals Revenue by Application (2020-2031)
12.4.1 SAMEA Generic and Biosimilar Pharmaceuticals Revenue by Application (2020-2025)
12.4.2 SAMEA Generic and Biosimilar Pharmaceuticals Revenue by Application (2026-2031)
12.5 SAMEA Generic and Biosimilar Pharmaceuticals Revenue Share by Application (2020-2031)
12.6 SAMEA Generic and Biosimilar Pharmaceuticals Revenue by Country
12.6.1 SAMEA Generic and Biosimilar Pharmaceuticals Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Generic and Biosimilar Pharmaceuticals Revenue by Country (2020-2025)
12.6.3 SAMEA Generic and Biosimilar Pharmaceuticals Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.